Antibody discovery and characterisation: Addressing challenging targets, developability, and immunogenicity
01 Dec 2025
Lead Identification & Optimization
- What are challenging targets?
- NGS + AI vs screening for candidate selection
- Antibody binding domains that will be used in non-classic IgG modalities
- Antibody characterisation: Affinity, functionality and epitope coverage. Where do current technologies need to improve?
- Developability and biophysical parameters. How can you keep them in focus from an early stage?
- Immunogenicity. Where do we stand?
Industry Expert
